Carmen G. Lechuga
Experimental Oncology,
Molecular Oncology Program,
Experimental Oncology, Molecular Oncology Program
Centro Nacional de Investigaciones Oncológicas (CNIO)
Carmen G. Lechuga has not added Biography.
If you are Carmen G. Lechuga and would like to personalize this page please email our Author Liaison for assistance.
Genetic analysis of Ras genes in epidermal development and tumorigenesis.
Small GTPases , 2013 | Pubmed ID: 24150175
Ras in epidermal proliferation.
Oncotarget Jul, 2014 | Pubmed ID: 25114036
Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2014 | Pubmed ID: 25288756
H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.
Cancer research Feb, 2017 | Pubmed ID: 27872088
Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway.
Methods in molecular biology (Clifton, N.J.) , 2017 | Pubmed ID: 27924574
Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF.
Cancer cell Apr, 2019 | Pubmed ID: 30975481
RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions.
Methods in molecular biology (Clifton, N.J.) , 2021 | Pubmed ID: 33977488
KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Proceedings of the National Academy of Sciences of the United States of America Jul, 2021 | Pubmed ID: 34301865
KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors.
Molecular oncology Sep, 2022 | Pubmed ID: 35313064
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.
Molecular cell Sep, 2022 | Pubmed ID: 36055235
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
The Journal of clinical investigation Apr, 2023 | Pubmed ID: 36928090
Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Jesús Frutos Díaz-Alejo*,1,2,3,4,
Simon April-Monn*,5,
Marina Cihova6,
Verona Buocikova6,
Jorge Villalón López1,3,
Maria Urbanova6,
Carmen G. Lechuga7,
Miroslav Tomas6,8,
Peter Dubovan6,8,
Bárbara Luna Sánchez3,
Sonia Camaño Páez3,
Alfonso Sanjuanbenito2,9,
Eduardo Lobo9,
Estefanía Romio de la Heras10,
Carmen Guerra2,7,
Carolina de la Pinta11,
Emma Barreto Melian1,2,
Mercedes Rodríguez Garrote1,2,
Alfredo Carrato1,2,4,
Laura Ruiz-Cañas3,12,13,
Bruno Sainz, Jr.2,3,12,13,
Ana Torres3,
Bozena Smolkova6,
Julie Earl1,2,3
1Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS),
2, The Biomedical Research Network in Cancer (CIBERONC),
3Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS),
4Faculty of Medicine, University of Alcalá de Henares,
5Institute of Tissue Medicine and Pathology, University of Bern,
6Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences,
7Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO),
8Department of Surgical Oncology, National Cancer Institute, Slovak Medical University,
9Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal,
10Department of Pathology, Hospital Universitario Ramón y Cajal,
11Department of Radiation Oncology, Hospital Universitario Ramón y Cajal,
12Department of Cancer, Instituto de Investigaciones Biomédicas “Alberto Sols” (IIBM),
13Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
